These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

406 related items for PubMed ID: 22169682

  • 1. Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease.
    Bosiers M, Scheinert D, Peeters P, Torsello G, Zeller T, Deloose K, Schmidt A, Tessarek J, Vinck E, Schwartz LB.
    J Vasc Surg; 2012 Feb; 55(2):390-8. PubMed ID: 22169682
    [Abstract] [Full Text] [Related]

  • 2. Primary everolimus-eluting stenting versus balloon angioplasty with bailout bare metal stenting of long infrapopliteal lesions for treatment of critical limb ischemia.
    Karnabatidis D, Spiliopoulos S, Diamantopoulos A, Katsanos K, Kagadis GC, Kakkos S, Siablis D.
    J Endovasc Ther; 2011 Feb; 18(1):1-12. PubMed ID: 21314342
    [Abstract] [Full Text] [Related]

  • 3. Everolimus-Eluting Stent for Patients With Critical Limb Ischemia and Infrapopliteal Arterial Occlusive Disease.
    Giaquinta A, Vincenzo A, De Marco E, Veroux M, Veroux P.
    Vasc Endovascular Surg; 2017 Feb; 51(2):60-66. PubMed ID: 28100126
    [Abstract] [Full Text] [Related]

  • 4. Outcome of a drug-eluting stent in longer below-the-knee lesions in patients with critical limb ischemia.
    Bosiers MJ, Deloose K, Peeters P, Torsello G, Zeller T, Scheinert D, Schmidt A, Maene L, Keirse K, Varcoe R, Bosiers M.
    J Cardiovasc Surg (Torino); 2017 Feb; 58(1):49-54. PubMed ID: 27455888
    [Abstract] [Full Text] [Related]

  • 5. Primary use of sirolimus-eluting stents in the infrapopliteal arteries.
    Rastan A, Schwarzwälder U, Noory E, Taieb FH, Beschorner U, Sixt S, Bürgelin K, Amantea P, Neumann FJ, Zeller T.
    J Endovasc Ther; 2010 Aug; 17(4):480-7. PubMed ID: 20681763
    [Abstract] [Full Text] [Related]

  • 6. Real-World Performance of Paclitaxel Drug-Eluting Bare Metal Stenting (Zilver PTX) for the Treatment of Femoropopliteal Occlusive Disease.
    Tran K, Ullery BW, Kret MR, Lee JT.
    Ann Vasc Surg; 2017 Jan; 38():90-98. PubMed ID: 27554688
    [Abstract] [Full Text] [Related]

  • 7. Sirolimus-eluting versus bare stents after suboptimal infrapopliteal angioplasty for critical limb ischemia: enduring 1-year angiographic and clinical benefit.
    Siablis D, Karnabatidis D, Katsanos K, Kagadis GC, Kraniotis P, Diamantopoulos A, Tsolakis J.
    J Endovasc Ther; 2007 Apr; 14(2):241-50. PubMed ID: 17484536
    [Abstract] [Full Text] [Related]

  • 8. Sirolimus-eluting stents for the treatment of infrapopliteal arteries in chronic limb ischemia: long-term clinical and angiographic follow-up.
    Werner M, Schmidt A, Freyer M, Bausback Y, Bräunlich S, Friedenberger J, Schuster J, Botsios S, Scheinert D, Ulrich M.
    J Endovasc Ther; 2012 Feb; 19(1):12-9. PubMed ID: 22313195
    [Abstract] [Full Text] [Related]

  • 9. First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease.
    Lammer J, Bosiers M, Zeller T, Schillinger M, Boone E, Zaugg MJ, Verta P, Peng L, Gao X, Schwartz LB.
    J Vasc Surg; 2011 Aug; 54(2):394-401. PubMed ID: 21658885
    [Abstract] [Full Text] [Related]

  • 10. Use of drug-eluting stents in patients with critical limb ischemia and infrapopliteal arterial disease: a real-world single-center experience.
    AbuRahma AF, Beasley M, Davis M, Adams E, Lee A, Shapiro J, Dean LS, Davis E.
    J Vasc Surg; 2021 Nov; 74(5):1619-1625. PubMed ID: 34182023
    [Abstract] [Full Text] [Related]

  • 11. One-Year Outcomes of the Paclitaxel-Eluting, Self-Expanding Stentys Stent System in the Treatment of Infrapopliteal Lesions in Patients With Critical Limb Ischemia.
    Bosiers M, Callaert J, Keirse K, Hendriks JMH, Peeters P, Verbist J, Maene L, Beelen R, Deloose K.
    J Endovasc Ther; 2017 Jun; 24(3):311-316. PubMed ID: 28351310
    [Abstract] [Full Text] [Related]

  • 12. Long-Term Follow-up of the PADI Trial: Percutaneous Transluminal Angioplasty Versus Drug-Eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia.
    Spreen MI, Martens JM, Knippenberg B, van Dijk LC, de Vries JPM, Vos JA, de Borst GJ, Vonken EPA, Bijlstra OD, Wever JJ, Statius van Eps RG, Mali WPTM, van Overhagen H.
    J Am Heart Assoc; 2017 Apr 14; 6(4):. PubMed ID: 28411244
    [Abstract] [Full Text] [Related]

  • 13. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
    Claessen BE, Smits PC, Kereiakes DJ, Parise H, Fahy M, Kedhi E, Serruys PW, Lansky AJ, Cristea E, Sudhir K, Sood P, Simonton CA, Stone GW.
    JACC Cardiovasc Interv; 2011 Nov 14; 4(11):1209-15. PubMed ID: 22115661
    [Abstract] [Full Text] [Related]

  • 14. Experience With the Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold in Arteries Below the Knee: 12-Month Clinical and Imaging Outcomes.
    Varcoe RL, Schouten O, Thomas SD, Lennox AF.
    JACC Cardiovasc Interv; 2016 Aug 22; 9(16):1721-8. PubMed ID: 27539693
    [Abstract] [Full Text] [Related]

  • 15. Commentary: infrapopliteal angioplasty with drug-eluting stents: from heart to toe.
    Siablis D, Katsanos K, Karnabatidis D.
    J Endovasc Ther; 2010 Aug 22; 17(4):488-91. PubMed ID: 20681764
    [No Abstract] [Full Text] [Related]

  • 16. Update on PADI trial: percutaneous transluminal angioplasty and drug-eluting stents for infrapopliteal lesions in critical limb ischemia.
    Martens JM, Knippenberg B, Vos JA, de Vries JP, Hansen BE, van Overhagen H, PADI Trial Group.
    J Vasc Surg; 2009 Sep 22; 50(3):687-9. PubMed ID: 19700099
    [Abstract] [Full Text] [Related]

  • 17. Sirolimus-eluting stents vs. bare-metal stents for treatment of focal lesions in infrapopliteal arteries: a double-blind, multi-centre, randomized clinical trial.
    Rastan A, Tepe G, Krankenberg H, Zahorsky R, Beschorner U, Noory E, Sixt S, Schwarz T, Brechtel K, Böhme C, Neumann FJ, Zeller T.
    Eur Heart J; 2011 Sep 22; 32(18):2274-81. PubMed ID: 21622669
    [Abstract] [Full Text] [Related]

  • 18. 3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions).
    Garg S, Serruys P, Onuma Y, Dorange C, Veldhof S, Miquel-Hébert K, Sudhir K, Boland J, Huber K, Garcia E, te Riele JA, SPIRIT II Investigators.
    JACC Cardiovasc Interv; 2009 Dec 22; 2(12):1190-8. PubMed ID: 20129545
    [Abstract] [Full Text] [Related]

  • 19. Paclitaxel-coated balloon angioplasty versus drug-eluting stenting for the treatment of infrapopliteal long-segment arterial occlusive disease: the IDEAS randomized controlled trial.
    Siablis D, Kitrou PM, Spiliopoulos S, Katsanos K, Karnabatidis D.
    JACC Cardiovasc Interv; 2014 Sep 22; 7(9):1048-56. PubMed ID: 25234679
    [Abstract] [Full Text] [Related]

  • 20. Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial.
    Wiemer M, Serruys PW, Miquel-Hebert K, Neumann FJ, Piek JJ, Grube E, Haase J, Thuesen L, Hamm C.
    Catheter Cardiovasc Interv; 2010 Jun 01; 75(7):997-1003. PubMed ID: 20517959
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.